NCT00543946View on ClinicalTrials.gov

Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese Males

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Arrhythmia
Interventions
DRUG

GAP-134

24-Hour IV infusion, SAD

Trial Locations (1)

141-0001

Shinagawa-Ku

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00543946 - Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese Males | Biotech Hunter | Biotech Hunter